Key statistics
On Friday, Natera Inc (NTRA:NSQ) closed at 127.78, -3.20% below its 52-week high of 132.01, set on Sep 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 126.49 |
---|---|
High | 128.40 |
Low | 124.79 |
Bid | 125.23 |
Offer | 128.18 |
Previous close | 127.13 |
Average volume | 1.21m |
---|---|
Shares outstanding | 123.68m |
Free float | 118.58m |
P/E (TTM) | -- |
Market cap | 15.80bn USD |
EPS (TTM) | -2.47 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
- First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
- Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
- Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Natera Reports Second Quarter 2024 Financial Results
- Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
- Natera to Report its Second Quarter 2024 Results on August 8, 2024
- New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
- Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
- Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
More ▼